Parnate Tapering Guide
tranylcypromine
Boxed Warning
Suicidality risk in children, adolescents, and young adults under 25 during initial antidepressant treatment.
Overview
Tranylcypromine is a non-selective irreversible MAOI structurally related to amphetamine, giving it a faster onset and mild stimulating quality compared with phenelzine. Same dietary and drug-interaction restrictions.
10mg tablets
Tablets: 10mg
Category C
Mechanism of Action
Irreversible inhibition of MAO-A and MAO-B; mild releasing effect on monoamines via amphetamine-like structure.
Taper Notes
Slow taper. Some members report mild stimulant-like withdrawal (fatigue, low motivation) given the amphetamine-related structure.
Hyperbolic Tapering Guidance
Same washout requirements as other irreversible MAOIs. Mild dependence-like features are reported but uncommon.
Summary written by TaperCommunity, informed by the Maudsley Deprescribing Guidelines (Horowitz & Taylor) and related literature — see Sources & References below. Not affiliated with or endorsed by the Maudsley.
Withdrawal Timeline
1-3 days after stopping
1-2 weeks
3-6 weeks
Mood and energy can take 1-2 months to stabilize
Common Withdrawal Symptoms
Interactions & Safety
Drug Interactions
- Same comprehensive list as phenelzine — see Nardil. Particularly dangerous with stimulants and decongestants given the amphetamine-like structure.
Contraindications
- Same as phenelzine
Toxicity
Same as phenelzine: tyramine-induced hypertensive crisis, serotonin syndrome, sympathomimetic interactions.
Pharmacokinetics
ADME Profile
Hepatic.
Need a clinician who understands tapering?
Browse our map of deprescribing-informed providers worldwide.
Other Drug Profiles
Sources & References
Parnate (tranylcypromine) information on this page is sourced from peer-reviewed research, regulatory bodies, clinical guidelines, and patient-advocacy organizations.
Encyclopedic & chemical databases
Neutral, high-authority entity references.
Regulatory sources
Official prescribing information and safety notices.
Peer-reviewed research
Primary literature cited in this taper guide.
- Horowitz MA, Taylor D 2019 — Tapering of SSRI treatment to mitigate withdrawal symptoms (hyperbolic taper) (The Lancet Psychiatry)
- Davies J, Read J 2019 — A systematic review into the incidence, severity and duration of antidepressant withdrawal effects (Addictive Behaviors)
- Framer A 2021 — The patient voice: an exploration of the experience of withdrawal from antidepressants (Therapeutic Advances in Psychopharmacology)
Clinical guidelines
Evidence-based deprescribing and prescribing standards.
Deprescribing-specific resources
Clinician-facing references on tapering protocols.
- Deprescribing.org — Evidence-based deprescribing algorithms from the Bruyère Research Institute
- Royal College of Psychiatrists — Stopping antidepressants — UK clinical guidance on safely discontinuing antidepressants
Patient-advocacy & lived-experience
Long-running communities documenting withdrawal experience.
- Surviving Antidepressants — tapering forum — Long-running community archive of antidepressant taper experiences
- Inner Compass Initiative — Withdrawal Project — Peer-led resources for psychiatric drug withdrawal
- Mad in America — antidepressant withdrawal archive — Journalism and personal narratives on SSRI/SNRI discontinuation
- RxISK — adverse drug reaction reporting — Independent database of patient-reported adverse effects
TaperCommunity does not provide medical advice. Always consult a qualified prescriber before adjusting psychiatric medication.